Monocyte chemoattractant protein-1: A key mediator of angiotensin II-induced target organ damage in hypertensive heart disease?

Journal of Hypertension

Volumn 22, Issue 3, 2004, Pages 451-454

  Zhuo, Jia L ^a,b  

^a Henry Ford Health Science Center   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDRALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; QUINAPRIL; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DRUG DESIGN; DRUG EFFECT; EDITORIAL; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; MACROPHAGE MIGRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RISK FACTOR; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 1642320333     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200403000-00003     Document Type: Editorial

References (26)

1. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Joon KP, et al. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999; 33:212-218.
2. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response, a new perspective. Hypertension 1995; 25:155-161.
3. Cushman WC. Are there benefits to specific antihypertensive drug therapy? Am J Hypertens 2003; 16:31-35.
4. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-251.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
7. Behr TM, Willette RN, Coatney RW, Berova M, Angermann CE, Anderson K, et al. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial MCP-1 and inflammation in hypertensive heart disease. J Hypertens 2004; 22: 583-592.
8. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988; 58:249-261.
9. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Srakioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88:5252-5256.
10. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, et al. Elevated expression of monocyte chemoattractant protein-1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992; 89:6953-6957.
11. Capers Q, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30:1397-1402.
12. Behr TM, Wang XK, Aijar N, Coatney RW, Li X, Koster P, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume overloaded congestive heart failure. Circulation 2000; 102:1315-1322.
13. Hilgers KF, Hartner A, Porst M, Mai M, Wittmann M, Hugo C, et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int 2000; 58:2408-2419.
14. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532-1541.
15. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Anglotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; 62 (suppl 82):12-22.
16. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NF-kappa B-mediated genes and downregulation of PPARs. Physiol Genom 2002; 11:21-31.
17. Yoshimura T, Leonard EJ. Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes. J Immunol 1990; 145:292-297.
18. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein-1 receptors reveals alternative splicing of the carboxyl-terminal trails. Proc Natl Acad Sci USA 1994; 91:2752-2756.
19. Tadashi K, Matsumori A, Ono K, Ito H, Matsushima K, Sasayama S. Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Lab Invest 2000; 80:1127-1136.
20. Hisada Y, Sygaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, et al. Angiotensin II plays a pathologic role in immune-mediated renal injury in mice. J Clin Invest 1999; 103:627-635.
21. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001; 38:100-104.
22. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001; 104: 2716-2721.
23. Jiang MJ, Yu YJ, Chen YL, Lee YM, Hung LS. Cyclic strain stimulates monocyte chemoattractant protein-1 mRNA expression in smooth muscle cells. J Cell Biochem 1999; 76:303-310.
24. Sozzani S, Luini W, Molino M, Jilek P, Bottazzi B, Cerletti C, et al. The signaling transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol 1991; 147:2215-2221.
25. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83:952-959.
26. 2+ influx, synergism with platelet-activating factor and significance for chemotaxis. J Biol Chem 1994; 269:4746-4753.